CMMB double bottom supply line test might end up in a breakoutIf it can hold the double bottom, it can play out the divergence and push upwards.
CMMB trade ideas
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) My opinion remains intact about this small bio cap. I will not sell a single share below $40 unless something bad happens, but that does not seem to be the case according to the recent news and reports. The stock has been falling on very low volume. The company has a great pipeline and the existing cash position is expected to fund the Company's current operating plan until mid 2023. The stock market is a device for transferring money from the impatient to the patient" Warren Buffet. I remember being called a pumper on PLUG or MARA when the stocks were trading at $2. NOTE: The 2 Wall Street analysts offering 12-month price forecasts for Chemomab Therapeutics Ltd have a median target of 43.50, with a high estimate of 45.00 and a low estimate of 42.00
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) With Friday’s breakout movement above 18 on decent volume, the downtrend is over. A break higher above the recent highs 19.35 would help the stock move to the $22.75-$24 area. Momentum indicators are turning up, a positive sign.
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) My long position on this small bio play remains intact. On the technical side, the stock has been pulling back on low volume to test the breakout zone around the $20 area. If this zone is respected next week, I expect that the next rebound will push the price up to $27. Money flow has been very solid over the past days and the accumulation/distribution continues to be bullish, we just might be on our way to higher prices. NOTE: The company has a poster presentation scheduled for Wednesday at the International Liver Congress 2021 (EASL). Analysts' price target range consensus $43
CMMBI think Chemomab Therapeutics Ltd (NASDAQ:CMMB) is building a nice base for take off. Some technical indicators are showing positive divergences on a daily basis. We could be in the early stages of a nice rally for this stock. Keep a close eye on it going forward. The stock currently trades at just over $18 a share, but analysts have targets pegged as high as $45 a share, suggesting as much as 120% upside.
Short Squeeze - CMMBIdea for Chemomab Therapeutics Ltd.:
- 131% borrow fee for shares. 47 shares available for borrow, according to iborrowdesk.
- Bottom of Risk Range:
- S3 Filing Sales Agreement with Cantor Fitzgerald & Co. dated Apr 30, 2021. fintel.io
- Cantor Fitzgerald assigned overweight rating on CMMB and raised price target to $45. www.marketbeat.com
- Good short squeeze material.
- Non Optionable.
Bought the shares $16.69
Expect share dilution $40-$50
GLHF
- DPT
CMMBI've mentioned Chemomab Therapeutics Ltd (NASDAQ:CMMB) for the bulls out there. On Friday, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $42 per share. It seems that analysts are also seeing what I'm seeing, a stock trading at bargain prices with a tremendous potential going forward and a very low float. From a technical standpoint, the stock has built a good support around $19.2 and $20 recently and does have the chance to go up. Any breakout above the $25 level next week would be a positive sign.
CMMBChemomab Therapeutics Ltd (NASDAQ:CMMB) This is a stock that I like a lot for another big rally. In the last couple of times it went under $30, the stock had a big spike right after. Don't worry with the SEC Form S-3 filed on Friday, for me means news ahead, before the raise ;) read the market behind the appearances and understand the hidden signals coming from this news that give us golden clues. Experienced traders know exactly how this works. For some reason, the stock recovered in after-hours following the S-3 announcement ;)
Anchiano and Chemomab merge, 16:1 reverse split$CMMB = New $ANCN
Chemomab just merged with Anchiano
There was a 16:1 reverse split on ANCN shares last nigth as part of the merger
